Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 874

1.

Antimicrobial resistance in gram-positive bacteria.

Rice LB.

Am J Med. 2006 Jun;119(6 Suppl 1):S11-9; discussion S62-70. Review.

PMID:
16735146
2.

Antimicrobial resistance in gram-positive bacteria.

Rice LB.

Am J Infect Control. 2006 Jun;34(5 Suppl 1):S11-9; discussion S64-73. Review.

PMID:
16813977
4.

[Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].

Li JT, Li Y, Wang J; China Bacterial Resistance Surveillance Study Group.

Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):365-74. Chinese.

PMID:
12820911
5.
6.

[Vancomycin resistant enterococci in the Netherlands].

Leavis HL, Willems RJ, Mascini EM, Vandenbroucke-Grauls CM, Bonten MJ.

Ned Tijdschr Geneeskd. 2004 May 1;148(18):878-82. Review. Dutch.

PMID:
15152389
7.
8.

Gram positive infection in trauma patients: new strategies to decrease emerging Gram-positive resistance and vancomycin toxicity.

Ginzburg E, Namias N, Brown M, Ball S, Hameed SM, Cohn SM.

Int J Antimicrob Agents. 2000 Nov;16 Suppl 1:S39-42.

PMID:
11137408
10.

New therapeutic agents for resistant Gram-positive infections.

Ziglam H, Nathwani D.

Expert Rev Anti Infect Ther. 2003 Dec;1(4):655-65. Review.

PMID:
15482162
11.

Antimicrobial resistance among gram-positive organisms in the intensive care unit.

Clark NM, Hershberger E, Zervosc MJ, Lynch JP 3rd.

Curr Opin Crit Care. 2003 Oct;9(5):403-12. Review.

PMID:
14508154
12.

Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.

Mauldin PD, Salgado CD, Durkalski VL, Bosso JA.

Ann Pharmacother. 2008 Mar;42(3):317-26. doi: 10.1345/aph.1K501. Epub 2008 Feb 19.

PMID:
18285560
13.

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.

Rubinstein E, Bompart F.

J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. Review.

15.

Future trends in the treatment of serious Gram-positive infections.

Metzger R, Bonatti H, Sawyer R.

Drugs Today (Barc). 2009 Jan;45(1):33-45. doi: 10.1358/dot.2009.45.1.1315922. Review.

PMID:
19271030
16.
19.

Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci.

Leclercq R.

Clin Microbiol Infect. 2009 Mar;15(3):224-31. doi: 10.1111/j.1469-0691.2009.02739.x. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk